Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
IND application for EB-003 expected in early 2026
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Athena is also exploring the use of this technology for expanded carrier screening
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Subscribe To Our Newsletter & Stay Updated
